BioCardia, Inc. Files 8-K on Financials
Ticker: BCDA · Form: 8-K · Filed: Aug 11, 2025 · CIK: 925741
| Field | Detail |
|---|---|
| Company | Biocardia, Inc. (BCDA) |
| Form Type | 8-K |
| Filed Date | Aug 11, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 B |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-condition, results-of-operations, filing
TL;DR
BioCardia dropped an 8-K on Aug 11th detailing financials. Check it out.
AI Summary
BioCardia, Inc. filed an 8-K on August 11, 2025, reporting on its results of operations and financial condition. The filing includes financial statements and exhibits, with the company's fiscal year ending on December 31st. BioCardia, Inc. is incorporated in Delaware and operates in the biological products sector.
Why It Matters
This 8-K filing provides investors with an update on BioCardia's financial performance and condition, which is crucial for evaluating the company's health and future prospects.
Risk Assessment
Risk Level: low — This is a routine filing of financial information and does not indicate any immediate or significant risks.
Key Players & Entities
- BioCardia, Inc. (company) — Registrant
- August 11, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- December 31 (date) — Fiscal year end
FAQ
What specific financial information is being reported in this 8-K filing?
The filing is categorized under 'Results of Operations and Financial Condition' and includes 'Financial Statements and Exhibits'.
When was the earliest event reported in this filing?
The earliest event reported is dated August 11, 2025.
In which state is BioCardia, Inc. incorporated?
BioCardia, Inc. is incorporated in Delaware.
What is the fiscal year end for BioCardia, Inc.?
The fiscal year end for BioCardia, Inc. is December 31.
What is the SIC code and industry classification for BioCardia, Inc.?
The Standard Industrial Classification (SIC) code is 2836, for BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES).
Filing Stats: 505 words · 2 min read · ~2 pages · Grade level 10 · Accepted 2025-08-11 09:15:53
Key Financial Figures
- $0.001 B — ch registered Common Stock, par value $0.001 BCDA The Nasdaq Capital Market Warrant
Filing Documents
- bcda20250811_8k.htm (8-K) — 30KB
- ex_850763.htm (EX-99.1) — 97KB
- 0001437749-25-025827.txt ( ) — 282KB
- bcda-20250811.xsd (EX-101.SCH) — 4KB
- bcda-20250811_def.xml (EX-101.DEF) — 13KB
- bcda-20250811_lab.xml (EX-101.LAB) — 17KB
- bcda-20250811_pre.xml (EX-101.PRE) — 13KB
- bcda20250811_8k_htm.xml (XML) — 5KB
02
Item 2.02. Results of Operations and Financial Condition. On August 11, 2025, BioCardia, Inc. issued a press release announcing its financial results for the quarter ended June 30, 2025. A copy of the press release is furnished as Exhibit 99.1 to this report. The information in this Item 2.02, including the Exhibit 99.1 attached hereto, is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of such section, nor shall it be deemed incorporated by reference in any filing under the Exchange Act or the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 BioCardia, Inc. press release dated August 11, 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. BIOCARDIA, INC. /s/ Peter Altman, Ph.D. Peter Altman, Ph.D. President and Chief Executive Officer Date: August 11, 2025